Introduction {#sec1}
============

Hand, foot, and mouth disease (HFMD) is a viral and febrile disease frequently seen in children, generally presenting with a mild course and accompanied by oral rash and rashes on palmar surfaces of hand and feet ([@bib16]). Cases of HFMD are seen all over the world; however, epidemics with serious complications that result in deaths are reported mostly from Western Pacific Region countries ([@bib27]). *Enterovirus* A species are responsible for more than 90% of HFMD cases. Coxsackievirus A (CV-A) 2, 3, 5, 6, 7, 8, 10, 12, 14, 16, and enterovirus A71 (EV-A71) belong to this group. It is known that epidemics are induced by CV-A16 and EV-A71, while other enteroviruses may cause sporadic cases ([@bib17]; [@bib1]).

CV-A6 was identified, for the first time, as the causative agent for HFMD in an epidemic that emerged in Finland in 2008 ([@bib20]). Following this, the identification of CV-A6 as the major causative agent for HFMD epidemics continued to occur in France, Spain and other European countries in 2009--2011 ([@bib3]; [@bib18]). HFMD epidemics caused by CV-A6 were also reported in the Western Pacific Region and the Americas after 2009 ([@bib5]; [@bib6]; [@bib10]; [@bib9]; [@bib12]; [@bib13]). More severe clinical course and widespread skin rashes were seen in cases caused by CV-A6, different from typical HFMD ([@bib21]).

Cases with no severe clinical course can be diagnosed with clinical findings without the need for microbiological diagnostic tests. However, certain serotypes may lead to severe disease ([@bib21]). Serotypes may vary within and among countries. Therefore, determination of the causative serotype is important for public health as well as for the design and implementation of the preventive measures. Recent increases in movements of people between countries and continents could be influential in the spread of different viral serotypes. Full identification of the causative organism could also provide information for the vaccine development studies in addition to its epidemiological importance ([@bib27]).

The published research on HFMD in Turkey has been generally towards the clinical aspects of the disease ([@bib8]; [@bib7]; [@bib4]). Apart from a single case study, no detailed investigations on the viral agent itself have been conducted ([@bib15]). In this investigation, we aimed to determine the serotype distribution in HFMD cases in children.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Patient Selection.** Our study cohort consisted of children applied to the outpatient clinics of the Pediatric Infectious Disease Department of Bezmialem Vakif University Hospital between January 2015 and November 2017. These consecutive patients were selected who complained of fever and rash on the hands, mouths or on the body including the legs (Fig. [1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and who were later clinically diagnosed with HFMD. An approval from Bezmialem Vakıf University Ethics Committee for Experimentation Involving Human Subjects was obtained before the study and informed consent was obtained from all families of the subjects.

![Patients with typical lesions on the hands.](pjm-68-2-165-g001){#fig1}

![Patients with mouth ulcers.](pjm-68-2-165-g002){#fig2}

![Patient with generalized lesions on the legs.](pjm-68-2-165-g003){#fig3}

**Sample Collection and Storage.** Samples were taken from at least two lesions in oral mucosa or trunk of patients with clinical symptoms of HFMD. Sterile cotton swabs wetted with saline (0.9% NaCl) were used for sampling. The samples were stored at --80°C in 1.5 ml sterile tubes containing phosphate buffered saline (PBS) until further processed.

**RNA isolation.** Direct-zol RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA) was used for nucleic acid extraction directly from patient samples and from supernatants obtained after viral culture. Manufacturer's instructions were followed for the entire procedure.

**Reverse transcription.** SensiFAST cDNA Synthesis Kit (Bioline, London, UK) was used to synthesize cDNA from isolated viral RNAs using random primers and the manufacturer's instructions were followed at all steps. cDNA was purified from reverse transcription products with Zymo Research DNA Clean & Concentrator™-5 kit in accordance with the manufacturer's instructions.

**Designing primers and PCR.** Pan-enterovirus primers specific to the *Enterovirus* genus targeting 5'UTR were designed for nested-PCR on basis of previously published studies ([@bib11]). In addition, specific primers targeting VP1 gene were used for EV-A71 and CV-A16 (Table [I](#tbl1){ref-type="table"}). A commercial kit (Illustra™ Hot Start Master Mix, GE Healthcare, Buckinghamshire, UK) was used for PCR. The reaction mixture contained 0.5 μmol forward primer, 0.5 μmol reverse primer, 1 μl (1--4 μg/μl) post clean-up purified cDNA, and 22 μl DNase-RNase free water added to the master mix kept ready in PCR tubes. Veriti® thermal cycler (Applied Biosystems, Foster City, CA, USA), was programmed as 94°C for 3 min initial incubation, 30 cycles of 94°C for 30 sec, 59°C for 30 sec, 72°C for 30 sec and 72°C for 5 min in order to amplify the Pan-EV, CV-A16 and EV-A71 specific products.

###### 

Primers used for PCR.

![](pjm-68-2-165-t001)

  Target Serotype      Orientation                   Sequence
  -------------------- ----------------------------- ---------------------------
  Pan-EV-5'UTR Outer   Forward                       5'-CYTTGTGCGCCTGTTTT-3'
  Reverse              5'-ATTGTCACCATAAGCAGCC-3'     
  Pan-EV-5'UTR-Inner   Forward                       5'-CAAGYACTTCTGTMWCCCC-3'
  Reverse              5'-CCCAAAGTAGTCGGTTCC-3'      
  EV-A71-VP1           Forward                       5'-AGAGCATGATTGAGACACG-3'
  Reverse              5'-RTCTTTCTCYTGTTTGTGTTC-3'   
  CV-A16-VP1           Forward                       5'-TGCAGACATGATTGACCAG-3'
  Reverse              5'-TGCCTACAGTTCTGATGCTA-3'    

The amplification products and the 100 bp marker were loaded into 1.5% agarose gel, electrophoresed for 40 minutes under 80 V, and analyzed in Molecular Imager Gel Doc XR System (BioRad, Hercules, CA, U.S.A.) imaging device.

**Cell culture.** Vero E6 cells were cultured *in vitro* with DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (Gibco) in 5% CO~2~ medium at 37°C. Samples were filtered through 0.45 μm filters and then added to monolayers of Vero E6 cell cultures. The infected cells were examined after 3 days of incubation for evaluation of *Enterovirus* specific cytopathic effects. Reverse-transcription PCR was performed with cell culture supernatants to confirm the PCR results of the patient samples.

**Sanger sequencing and phylogenetic analysis.** The sequencing of the amplified product was carried out by the Sentegen Biyotek (Ankara, Turkey) to determine the serotype of *Enterovirus* detected in the samples.

The sequences of PCR products were assembled and edited using BioEdit version 7.0.5 (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>). This sequence was compared with the sequences deposited in GenBank of the National Center for Biotechnology Information (NCBI) by means of the BLASTN 2.2.19 option. The consensus sequence was compiled in a FASTA file for the phylogenetic analysis and aligned with the Clustal W 1.8.1. profile mode included in the Mega 4.0.2 (<https://www.megasoftware.net/mega4/>) software.

Results {#sec4}
=======

Eleven of 27 children included in the study were female and 16 were male. The ages ranged from 4 months to 9 years, and 21 of the 27 children were aged between 1 and 3 years (78%). Eighteen of the patients (67%) applied to the hospital during the summer months. In the cohorts, neither systemic blisters nor high fever was noted. None of our patients needed hospitalization. There were no severe complications such as meningitis and encephalitis. Only three of 27 patients applied to the hospital with nail shedding after the recovery period of approximately six weeks.

A total of 27 patient samples, 15 from the 2015--2016 season and 12 from 2017, were included in the study. The nested PCR results of 12 patients, sampled in 2015--2016, revealed products with a length of 530 and 389 bp (Fig. [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) that corresponded to the pan-enterovirus outer and inner primers, respectively. This finding was interpreted as proof of the *Enterovirus* content in the samples. No positive results were observed after PCR performed with the species-specific primers targeting CV-A16 and EV-A71 viruses. To confirm the presence of enteroviral genetic material, all 12 PCR positive products were sequenced. Sequencing revealed that nine of these samples were consistent with the CV-A6 sequences but the remaining samples were not (Table [II](#tbl2){ref-type="table"}). Afterward, a confirmatory species-specific PCR affirmed that the samples were indeed CV-A6 (Fig. [6](#fig6){ref-type="fig"}).

![The samples were subjected to the pan-enterovirus specific nested PCR with outer primers where 530 bp products were amplified. Left to right, line 1: 100 bp marker, lines 2 to 5: HFM-2 to HFM-5, line 6: HFM-7, line 7: HFM-9, lines 8 to 14: HFM-10 to HFM-16.](pjm-68-2-165-g004){#fig4}

![The samples were subjected to the pan-enterovirus specific nested PCR with inner primers where 389 bp products were amplified. Left to right, line 1: 100 bp marker, lines 2 to 5: HFM-2 to HFM-5, line 6: HFM-7, line 7: HFM-9, lines 8 to 14: HFM-10 to HFM-16.](pjm-68-2-165-g005){#fig5}

###### 

Phylogenetic identities of the coxsackievirus A isolates, based on VP1 sequences.
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  Isolate code   Primer        Nearest phylogenetic neighbours   Identity percentage
  -------------- ------------- --------------------------------- ---------------------
  HFM-2          153 F/541 R   Coxsackievirus A6                 99%
  HFM-5          153 F/541 R   Coxsackievirus A6                 99%
  HFM-9          153 F/541 R   Coxsackievirus A6                 99%
  HFM-10         153 F/541 R   Coxsackievirus A6                 99%
  HFM-11         153 F/541 R   Coxsackievirus A6                 99%
  HFM-12         153 F/541 R   Coxsackievirus A6                 99%
  HFM-14         153 F/541 R   Coxsackievirus A6                 99%
  HFM-15         153 F/541 R   Coxsackievirus A6                 99%
  HFM-16         153 F/541 R   Coxsackievirus A6                 99%
  HFM24          153 F/541 R   Coxsackievirus A16                99%
  HFM25          153 F/541 R   Coxsackievirus A16                99%
  HFM26          153 F/541 R   Coxsackievirus A16                97%

![CV-A6 specific primers amplified products of approximately 645 bp.](pjm-68-2-165-g006){#fig6}

Twelve patient samples from 2017, were amplified by PCR and seven samples were positive for *Enterovirus*. These samples were directly subjected to sequencing without serotype-specific PCR for EV-A71 and CV-A16, since the previous samples were negative. Three of the seven samples were CV-A16 according to the results of sequencing (Fig. [7](#fig7){ref-type="fig"}).

![Phylogenetic analysis of clinical isolates. Phylogenetic analysis of coxsackievirus A6 nucleotide sequences that were obtained using 153F ve 541R primers, showed the relationships between the clinical CV-A6 and the CV-A16 isolate selected from the GenBank. A scale bar indicates branch distances. The phylogenetic tree was constructed using neighbour-joining method and validated with 1000 pseudo-replicates. Poliovirus (NC 002058.3) was selected as out-group.](pjm-68-2-165-g007){#fig7}

All the samples were inoculated into the Vero E6 cell line and characteristic cytopathic effects were noticed after 3-days incubation. The supernatant samples were collected and the PCR test was carried out with pan-enterovirus primers (data not shown). It was noticed that the results were compatible with the PCR performed directly from the patient samples.

Discussion {#sec5}
==========

Hand, foot, and mouth disease epidemics are mostly caused by EV-A71 and CV-A16. Recently, CV-A6 has been identified as the agent of epidemics causing severe forms of the disease with general skin involvement. Similar epidemics that started in Finland in 2008 were also reported from Singapore in 2009, France and Taiwan in 2010, and the USA, Cuba, Spain, Japan, and China in 2011 ([@bib1]). In this study, CV-A6 was found to be the causative agent in 75% of the cases what was confirmed by sequencing (Table [III](#tbl3){ref-type="table"}). This result is consistent with the current literature that reports an increase in CV-A6 incidence ([@bib1]). HFMD is not a mandatory disease to report to public health authorities in Turkey. Therefore, complete data on the causative agents of the cases throughout the country is not yet known. Only a single case study identifying the causative agent was reported from Turkey ([@bib15]). In that study, the identification of CV-16 in a 39 years old male patient was performed. The present study identified CV-A16 in 25% of the pediatric samples (Table [III](#tbl3){ref-type="table"}). A study conducted in China between 2011 and 2015 on 2130 samples positive for *Enterovirus* demonstrated that CV-A16 was identified in 32%, and EV-A71 -- in 30% of the samples ([@bib22]). It has been reported that EV-A71 infections may lead to neurological complications (e.g. aseptic meningitis, acute flaccid paralysis, and brainstem encephalitis), and mortality. All of the cases in our study were from outpatient services and no EV-A71 was identified in any patients. The literature reported severe cases with CV-A6 but none of our patients had a complicated course of the disease and needed hospitalization ([@bib28]). Another clinical feature of CV-A6 is onychomadesis, ([@bib26]) and in our cohorts, only one of the confirmed CV-A6 cases was re-admitted to the hospital at the 6^th^ week after the discharge with complaints of onychomadesis.

###### 

The patients' samples and their positivity for coxsackievirus A6 and A16.
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  Year         No. of samples   *Enterovirus* positivity   Coxsackievirus A6 positivity   Coxsackievirus A16 positivity
  ------------ ---------------- -------------------------- ------------------------------ -------------------------------
  2015--2016   15               12                         9                              0
  2017         12               7                          0                              3
  Total        27               19                         9                              3

The frequency of HFMD emergences peak twice in a year in countries with a tropical climate; however, it can be observed throughout the year. It exhibits a single annual rise in summer or fall in countries located at higher latitudes ([@bib2]; [@bib14]; [@bib25]). In Turkey, individual studies showed that the frequency of HFMD rises during summer ([@bib23]; [@bib24]; [@bib29]). In parallel with the previous research, in the present study, it has been observed that the majority of HFMD cases (67%) applied to our hospital during summer months.

Hand, foot, and mouth disease frequently affects children under the age of 5. Previous studies show that more than half of the individuals affected by epidemics were aged between 1 and 3 years ([@bib19]; [@bib14]). Seventy-eight percent of 27 children included in the current study was aged between 1 and 3 years. Epidemiological studies investigating HFMD have shown that the incidence is 1.5--2 times higher among boys compared to girls ([@bib14]; [@bib22]). In this study, similarly, the ratio of boys/girls was 16/11.

One of the limitations of the current study is that our cohorts were from a single city and the numbers of the patient were rather small. Therefore, our result might not reflect the overall HFMD epidemiology of all country. Secondly, only 12 sequencing results could be used to make the evolutionary trees to establish the relationship of the CV-A6, or CV-A16 in Turkey in relation to others in the world. Therefore further studies including samples from various regions of Turkey with a larger sampling might shed a better light on the dissemination as well as the phylogenetic relationships of these viral agents. Nevertheless, the data presented in the current study reports for the first time a detailed investigation about the presence of previously unnoticed serotypes on an important public health agent.

Geographically, Turkey acts as a gateway between Asia and Europe, and receives an influx of tourists from various countries across the world during summer months, the time that the incidence of HFMD peaks. Therefore, the establishment of a national surveillance system for HFMD and identification of causative serotype agents are important from an epidemiological point of view as well as for the planning and execution of preventive measures including vaccination. Our investigation and reporting might be useful in guiding these efforts.
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